(RTTNews) - French drug major Sanofi (SNY)' reported Thursday higher profit in its first quarter, with growth in net sales. Further, the company confirmed its fiscal 2025 outlook. In the first ...

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback) 6 Sanofi intends to complete a share buyback program ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary ...

Claim your 7-day free trial now. Sanofi SA SNY reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant ...